Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

A brief review of biomarkers for preventing and treating cardiovascular diseases.

Sun X, Jia Z.

J Cardiovasc Dis Res. 2012 Oct;3(4):251-4. doi: 10.4103/0975-3583.102688.

2.

Serum creatinine vs. albuminuria as biomarkers for the estimation of cardiovascular risk.

Kalaitzidis RG, Bakris GL.

Curr Vasc Pharmacol. 2010 Sep;8(5):604-11. Review.

PMID:
20507275
3.

The prognostic value of the QT interval and QT interval dispersion in all-cause and cardiac mortality and morbidity in a population of Danish citizens.

Elming H, Holm E, Jun L, Torp-Pedersen C, Køber L, Kircshoff M, Malik M, Camm J.

Eur Heart J. 1998 Sep;19(9):1391-400.

PMID:
9792266
4.

Biomarkers in clinical medicine.

Chen XH, Huang S, Kerr D.

IARC Sci Publ. 2011;(163):303-22. Review.

PMID:
22997869
5.

Are biomarkers useful for assessing cardiovascular risk in patients with chronic kidney disease?

Rubin C, Nolin TD, Himmelfarb J.

Curr Opin Nephrol Hypertens. 2007 Nov;16(6):506-11. Review.

PMID:
18089962
6.

[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].

Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, Maison P, Terra JL, Azorin JM; avec le soutien institutionnel du laboratoire Lilly..

Encephale. 2009 Sep;35(4):330-9. doi: 10.1016/j.encep.2008.10.014. Epub 2009 Jul 9. French.

PMID:
19748369
7.

Frequency and prognostic significance of QT prolongation in chronic renal failure patients.

Voiculescu M, Ionescu C, Ismail G.

Rom J Intern Med. 2006;44(4):407-17.

PMID:
18386617
8.

Biomarkers for atherosclerosis: pathophysiological role and pharmacological modulation.

Ferri N, Paoletti R, Corsini A.

Curr Opin Lipidol. 2006 Oct;17(5):495-501. Review.

PMID:
16960497
9.

The comparison of QT dispersion and 24 hour ambulatory blood pressure monitoring amongst diabetic patients with and without microalbuminuria.

Yeo CK, Hapizah MN, Khalid BA, Wan Nazainimoon WM, Khalid Y.

Med J Malaysia. 2004 Jun;59(2):185-9.

10.

QT prolongation in patients with Type 2 diabetes and microalbuminuria.

Rutter MK, Viswanath S, McComb JM, Kesteven P, Marshall SM.

Clin Auton Res. 2002 Oct;12(5):366-72.

PMID:
12420081
11.

Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease.

Fraley AE, Tsimikas S.

Curr Opin Lipidol. 2006 Oct;17(5):502-9. Review.

PMID:
16960498
12.

Developing and assessing cardiovascular biomarkers.

Dadu RT, Nambi V, Ballantyne CM.

Transl Res. 2012 Apr;159(4):265-76. doi: 10.1016/j.trsl.2012.01.003. Epub 2012 Jan 27. Review.

PMID:
22424430
13.

Drug treatment for hypertensive patients in special situations: diabetes and hypertension.

Mogensen CE.

Clin Exp Hypertens. 1999 Jul-Aug;21(5-6):895-906. Review.

PMID:
10423111
14.

QT interval prolongation: prevalence, risk factors and pharmacovigilance data among methadone-treated patients in France.

Perrin-Terrin A, Pathak A, Lapeyre-Mestre M.

Fundam Clin Pharmacol. 2011 Aug;25(4):503-10. doi: 10.1111/j.1472-8206.2010.00871.x. Epub 2010 Sep 6.

PMID:
20825488
15.

Increased QT dispersion in the absence of QT prolongation in patients with Behcet's disease and ventricular arrhythmias.

Aytemir K, Ozer N, Aksoyek S, Ozcebe O, Kabakci G, Oto A.

Int J Cardiol. 1998 Dec 1;67(2):171-5.

PMID:
9891952
16.

Clinical determinants of increased QT dispersion in patients with diabetes mellitus.

Cardoso C, Salles G, Bloch K, Deccache W, Siqueira-Filho AG.

Int J Cardiol. 2001 Jul;79(2-3):253-62.

PMID:
11461749
17.

How-to guide on biomarkers: biomarker definitions, validation and applications with examples from cardiovascular disease.

Puntmann VO.

Postgrad Med J. 2009 Oct;85(1008):538-45. doi: 10.1136/pgmj.2008.073759. Review.

PMID:
19789193
18.

Cardiovascular biomarkers in CKD: pathophysiology and implications for clinical management of cardiac disease.

Roberts MA, Hare DL, Ratnaike S, Ierino FL.

Am J Kidney Dis. 2006 Sep;48(3):341-60. Review.

PMID:
16931208
19.

Cardiovascular characteristics in Marfan syndrome and their relation to the genotype.

De Backer J.

Verh K Acad Geneeskd Belg. 2009;71(6):335-71. Review.

PMID:
20232788
20.

Effectiveness of programmes as part of primary prevention demonstrated on the example of cardiovascular diseases and the metabolic syndrome.

Korczak D, Dietl M, Steinhauser G.

GMS Health Technol Assess. 2011 Apr 1;7:Doc02. doi: 10.3205/hta000093.

Supplemental Content

Support Center